Skip to main content

Ovarian Cancer

Telehealth Coverage Expanded During the COVID-19 Pandemic

Trabectedin Added to Pegylated Doxorubicin May Be Viable Treatment for Recurrent Ovarian Cancer But Platinum Remains Standard of Care

NORA Clinical Trial Confirms Efficacy of Individualized Niraparib Starting Dose to Treat Platinum-Sensitive Ovarian Cancer

Increased Uptake of Neoadjuvant Chemotherapy Does Not Explain Trend Toward Improved Survival in Advanced Ovarian Cancer

Platinum-Based Chemotherapy Following Progression on PARP Inhibitor Maintenance Yields Greatest Benefit in Advanced Ovarian Cancer with Platinum-Free Interval >12 Months

ASCO Guidelines Support PARP Inhibitor Use in Maintenance and Recurrent Setting of Advanced Ovarian Cancer

Niraparib Efficacy in Advanced Ovarian Cancer Extends to All Biomarker Subgroups

Olaparib/Bevacizumab as First-Line Maintenance Reduces Risk for Progression or Death in Patients with Advanced Ovarian Cancer

Online Delivery of Genetic Services: No Increase in Cancer Risk Distress versus Telephone Counseling

Phase 2 OVARIO Update: Promising Survival Rates in Patients with Advanced Ovarian Cancer Treated with Niraparib plus Bevacizumab Maintenance

5
6
7
8
9
10
11

Page 8 of 13
Results 71 - 80 of 125